Control group (n=44) Intervention group (n=45) p-value (t student or χ²)
Age (yr) 61,7 ± 4,0 59,4 ± 3,9 0.407a
Body mass index (kg/m2) 28,3 ± 1,7 27,2 ± 1,4 0.323 a
Number of men (n) 25 (56.8%) 30 (66.7%) 0.339 b
Social level (n)
1 19 (43.2%) 14 (31.1%) 0.419 b
2 7 (15.9%) 11 (24.4%)
3 18 (40.9%) 20 (44.4%)
Kidney failure (n) 8 (18.2%) 6 (13.3%) 0.530 b
Liver failure (n) 1 (2.3%) 0 (0%) NA
Number of total chronic disease (n)
1 8 (18.2%) 11 (24.4%) 0.613 b
2 12 (27.3%) 14 (31.1%)
>2 24 (54.5%) 20 (44.4%)
Number of diseases involved in the study (n)
1 36 (81.8%) 37 (82.2%) 0.960 b
Hypertension 22 (50.0%) 24 (53.3%) 0.613 b
Type 2 diabetes 7 (15.9%) 5 (11.1%)
Hypercholesterolemia 7 (15.9%) 8 (17.8%)
2 8 (18.2%) 7 (15.6%) 0.777 b
Hypertension + Type 2 diabetes 6 (13.6%) 6 (13.3%) 1 b
Hypertension + Hypercholesterolemia 0 (0.0%) 1 (2.2%) NA
Type 2 diabetes + Hypercholesterolemia 2 (4.5%) 0 (0.0%) NA
3 0 (0.0%) 1 (2.2%) NA
Number of different drugs prescribed 6,2 ± 1,2 5,0 ± 0,8 0.118 a
Adjusted number of different drugs prescribed (n)
<5 18 (40.9%) 18 (40.0%) 0.930 b
≥5 26 (59.1%) 27 (60.0%)
Side effects at the inclusion (n) 11 (25.0%) 9 (20%) 0.572 b
Adherence score at the inclusion 2,2 ± 0,4 2,0 ± 0,4 0.501 a
Patient with hypertension (n) 28 (63.6%) 32 (71.1%) 0.452 b
used as primary outcome (n) 28 (63.6%) 27 (60.0%) 0.724 b
Patient with type II diabetes (n) 15 (34.1%) 12 (26.7%) 0.446 b
used as primary outcome (n) 7 (15.9%) 9 (20.0%) 0.615 b
Patient with hypercholesterolemia (n) 9 (20.5%) 10 (22.2%) 0.839 b
used as primary outcome (n) 9 (20.5%) 9 (20%) 0.957 b
Lost of follow-up (n) 5 (11.4%) 11 (24.4%) 0.108 b